Belfast Health and Social Care Trust
caring supporting improving together

FOI/38484

29 October 2026

Biologics Medicines in Gastroenterology

1. **How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:**

   Adalimumab – Humira

   10

   Adalimumab Biosimilar

   300

   Etrasimod

   0

   Filgotinib

   22

   Golimumab – Simponi

   5

   Golimumab Biosimilar

   <5

   Infliximab – Remicade

   40

   Infliximab Biosimilar

   250

   Mirikizumab

   35

Ozanimod

<5

Risankizumab

70

Tofacitinib

<5

Upadacitinib

100

Ustekinumab – Stelara

<5

Ustekinumab Biosimilar

380

Vedolizumab

130

Guselkumab

35

2. **If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:**

Adalimumab – Humira

<5

Adalimumab Biosimilars

10

Golimumab – Simponi

5

Golimumab Biosimilar

0

Infliximab – Remicade

15

Infliximab Biosimilars

100

Risankizumab

<5

Upadacitinib

40

Ustekinumab – Stelara

0

Ustekinumab Biosimilar

100

Vedolizumab

90

Mirikizumab

34

Guselkumab

20

Where numbers are low, we have indicated less than five (<5) rather than provide the exact figure. Releasing such small numbers has the potential to make people identifiable and disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018. This information is therefore exempt from release under Section 40(2) of the Freedom of Information Act 2000 – Information Relating to a Third Party.